NYSEA:TOVX 15 October 2025

Theriva Biologics has been in the news for its upcoming conference presentations and strong trial data. On October 13, 2025 the company announced that expanded data from the VIRAGE Phase 2b trial will be presented at the ESMO 2025 Congress on October 20sec.gov. In VIRAGE, the oncolytic adenovirus VCN-01 is given with gemcitabine/nab‑paclitaxel standard chemotherapy. Interim abstract data show that VCN-01 + chemotherapy substantially improved overall survival and progression-free survival versus chemotherapy alonesec.govsec.gov. Patients receiving VCN-01 saw median OS up to ~11–14 months versus ~8–11 months on chemo alonesec.govsec.gov. Notably, patients given two doses of VCN-01 before the 4th chemo cycle showed a 14.8 vs. 11.6 month OS improvementsec.gov. The study met its primary endpoints, with VCN-01 being well tolerated.